Journal ArticleDOI
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
Dick de Zeeuw,Rajiv Agarwal,Michael Amdahl,Paul Audhya,Daniel W. Coyne,Tushar S. Garimella,Hans-Henrik Parving,Yili Pritchett,Giuseppe Remuzzi,Eberhard Ritz,Dennis L. Andress +10 more
TLDR
Addition of 2 μg/day paricalcitol to RAAS inhibition safely lowers residual albuminuria in patients with diabetic nephropathy, and could be a novel approach to lower residual renal risk in diabetes.About:
This article is published in The Lancet.The article was published on 2010-11-06. It has received 652 citations till now. The article focuses on the topics: Paricalcitol & Placebo.read more
Citations
More filters
Journal ArticleDOI
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
Ron T. Gansevoort,Ricardo Correa-Rotter,Brenda R. Hemmelgarn,Tazeen H. Jafar,Hiddo J.L. Heerspink,Johannes F.E. Mann,Kunihiro Matsushita,Chi Pang Wen +7 more
TL;DR: The epidemiology and pathophysiological mechanisms of cardiovascular risk in patients with chronic kidney disease are discussed, and methods of prevention are discussed.
Journal ArticleDOI
Cellular and molecular mechanisms of renal fibrosis
TL;DR: The current understanding of the cellular and molecular mechanisms of renal fibrosis is outlined, which could offer novel insights into the development of new therapeutic strategies.
Journal ArticleDOI
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease: The PRIMO Randomized Controlled Trial
Ravi Thadhani,Evan Appelbaum,Yili Pritchett,Yuchiao Chang,Julia Wenger,Hector Tamez,Ishir Bhan,Rajiv Agarwal,Carmine Zoccali,Christoph Wanner,Donald M. Lloyd-Jones,J.B. Cannata,B. Taylor Thompson,Dennis L. Andress,Wuyan Zhang,David K. Packham,David K. Packham,Bhupinder Singh,Daniel Zehnder,Amil M. Shah,Ajay Pachika,Warren J. Manning,Scott D. Solomon +22 more
Abstract: Context Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac structure and function, yet firm evidence for either remains lacking. Objective To determine the effects of an active vitamin D compound, paricalcitol, on left ventricular mass over 48 weeks in patients with an estimated glomerular filtration rate of 15 to 60 mL/min/1.73 m 2 . Design, Setting, and Participants Multinational, double-blind, randomized placebo-controlled trial among 227 patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction, conducted in 11 countries from July 2008 through September 2010. Intervention Participants were randomly assigned to receive oral paricalcitol, 2 μg/d (n =115), or matching placebo (n = 112). Main Outcome Measures Change in left ventricular mass index over 48 weeks by cardiovascular magnetic resonance imaging. Secondary end points included echocardiographic changes in left ventricular diastolic function. Results Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained levels within the normal range throughout the study duration. At 48 weeks, the change in left ventricular mass index did not differ between treatment groups (paricalcitol group, 0.34 g/m 2.7 [95% CI, −0.14 to 0.83 g/m 2.7 ] vs placebo group, −0.07 g/m 2.7 [95% CI, −0.55 to 0.42 g/m 2.7 ]). Doppler measures of diastolic function including peak early diastolic lateral mitral annular tissue velocity (paricalcitol group, −0.01 cm/s [95% CI, −0.63 to 0.60 cm/s] vs placebo group, −0.30 cm/s [95% CI, −0.93 to 0.34 cm/s]) also did not differ. Episodes of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group. Conclusion Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease. Trial Registration clinicaltrials.gov Identifier: NCT00497146
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease
Ravi Thadhani,Evan Appelbaum,Yili Pritchett,Julia Wenger,Hector Tamez,Ishir Bhan,Rajiv Agarwal,Carmine Zoccali,Christoph Wanner,Donald M. Lloyd-Jones,J.B. Cannata,B. Taylor Thompson,Dennis L. Andress,Wuyan Zhang,David K. Packham,Bhupinder Singh,Daniel Zehnder,Amil M. Shah,Warren J. Manning,Scott D. Solomon +19 more
TL;DR: Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease.
Journal ArticleDOI
Diabetic nephropathy - complications and treatment.
TL;DR: This review will examine the current concepts of diabetic nephropathy management in the context of some of the basic science and pathophysiology aspects relevant to the approaches taken in novel, investigative treatment strategies.
References
More filters
Journal ArticleDOI
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
Aram V. Chobanian,George L. Bakris,Henry R. Black,William C. Cushman,Lee A. Green,Joseph L. Izzo,Daniel W. Jones,Barry J. Materson,Suzanne Oparil,Jackson T. Wright,Edward J. Roccella +10 more
TL;DR: The most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivated, and empathy builds trust and is a potent motivator.
Journal ArticleDOI
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Aram V. Chobanian,George L. Bakris,Henry R. Black,William C. Cushman,Lee A. Green,Joseph L. Izzo,Daniel W. Jones,Barry J. Materson,Suzanne Oparil,Jackson T. Wright,Edward J. Roccella +10 more
TL;DR: In those older than age 50, systolic blood pressure of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP, and hypertension will be controlled only if patients are motivated to stay on their treatment plan.
Journal ArticleDOI
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
Koon K. Teo,Janice Pogue,Leanne Dyal,Ingrid Copland,Helmut Schumacher,Gilles R. Dagenais,Craig S. Anderson +6 more
TL;DR: Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema and a increased risk of hypotensive symptoms.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Aram V. Chobanian,George L. Bakris,Henry R. Black,William C. Cushman,Lee A. Green,Daniel W. Jones,Barry J. Materson +6 more
TL;DR: Aram V. Chobanian, MDGeorge L. Bakris, MDHenry R. Black, MDWilliam C. Cushman, MDLee A. Green, MD, MPHJoseph L. Izzo, Jr, MDDaniel W. Jones, MDBarry J. Materson, MBASuzanne Oparil, MDJackson T. Wright, Jr., MD, PhDEdward J. Roccella, PhD, MPHand the National High BloodPressure Education ProgramCoordinating Committee
Journal ArticleDOI
1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system
TL;DR: It is shown that renin expression and plasma angiotensin II production were increased severalfold in vitamin D receptor-null (VDR-null) mice, leading to hypertension, cardiac hypertrophy, and increased water intake, and 1,25(OH)(2)D(3) is a novel negative endocrine regulator of the renin-angiotens in system.
Related Papers (5)
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease: The PRIMO Randomized Controlled Trial
Ravi Thadhani,Evan Appelbaum,Yili Pritchett,Yuchiao Chang,Julia Wenger,Hector Tamez,Ishir Bhan,Rajiv Agarwal,Carmine Zoccali,Christoph Wanner,Donald M. Lloyd-Jones,J.B. Cannata,B. Taylor Thompson,Dennis L. Andress,Wuyan Zhang,David K. Packham,David K. Packham,Bhupinder Singh,Daniel Zehnder,Amil M. Shah,Ajay Pachika,Warren J. Manning,Scott D. Solomon +22 more